

Special Issue

Nanomedicine and Nanobiotechnology in Cancer

Message from the Guest Editor

Nanomedicine and nanobiotechnology have tremendous potential for tomorrow's patient care, particularly in cancer disease management. This Special Issue of *Cancers* aims to gather the numerous theoretical and research concepts in nanomedicine that are currently being translated into preclinical and clinical studies. This Special Issue is based on the fifth edition of the ICONAN conference, which will bring together high-profile plenary speakers and world-class researchers who have successfully developed and translated nanomedicines over the last decades. The use of nanomedicine/nanobiotechnology for imaging, diagnosis, biosensing, drug delivery, therapy, or any other use of nanotechnologies in relation with cancer and health are welcome.

Guest Editor

Dr. Anne-Marie Caminade

Laboratoire de Chimie de Coordination du CNRS, 205 Route de Narbonne, 31077 Toulouse, CEDEX 4, France

Deadline for manuscript submissions

closed (15 November 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/185640

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)